Targeted protein degradation (TPD) is becoming a popular choice for Korean pharma firms looking for new drug modalities and growth engines. They are making diverse moves, largely seeking R&D collaborations, M&A and investment.
Among them, SK Biopharmaceuticals Co., Ltd, an affiliate of SK Group, has made a strong move; it has announced...







